Olympiad Research LP Takes Position in Bioventus Inc. (NYSE:BVS)

Olympiad Research LP acquired a new stake in Bioventus Inc. (NYSE:BVS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 21,014 shares of the company’s stock, valued at approximately $251,000.

Other institutional investors have also modified their holdings of the company. Acadian Asset Management LLC bought a new stake in shares of Bioventus in the 1st quarter valued at approximately $28,000. Lazard Asset Management LLC bought a new stake in shares of Bioventus in the 1st quarter valued at approximately $40,000. HB Wealth Management LLC bought a new stake in shares of Bioventus in the 2nd quarter valued at approximately $60,000. SG Americas Securities LLC bought a new stake in shares of Bioventus in the 1st quarter valued at approximately $66,000. Finally, Burns Matteson Capital Management LLC purchased a new stake in shares of Bioventus in the second quarter worth approximately $67,000. 62.94% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director John A. Bartholdson acquired 25,500 shares of Bioventus stock in a transaction on Monday, August 19th. The shares were bought at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the acquisition, the director now directly owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director John A. Bartholdson acquired 80,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $8.55 per share, with a total value of $684,000.00. Following the purchase, the director now directly owns 6,913,857 shares of the company’s stock, valued at $59,113,477.35. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director John A. Bartholdson bought 25,500 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were acquired at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the transaction, the director now directly owns 6,939,357 shares in the company, valued at approximately $59,331,502.35. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 32.90% of the stock is currently owned by company insiders.

Bioventus Trading Down 0.4 %

Shares of NYSE BVS opened at $11.24 on Friday. The business’s 50 day moving average price is $11.72 and its 200-day moving average price is $8.33. The company has a market cap of $910.10 million, a price-to-earnings ratio of 36.08 and a beta of 0.88. Bioventus Inc. has a fifty-two week low of $3.36 and a fifty-two week high of $14.38. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33.

Bioventus (NYSE:BVS) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. The company had revenue of $138.96 million for the quarter, compared to the consensus estimate of $132.57 million. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. During the same period last year, the business posted $0.05 EPS. On average, sell-side analysts expect that Bioventus Inc. will post 0.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group increased their price target on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday. Craig Hallum increased their price target on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, September 27th.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.